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Abstract
We conducted data-mining analyses using the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) and molecular genetics of schizophrenia genome-wide association study
supported by the genetic association information network (MGS-GAIN) schizophrenia data sets
and performed bioinformatic prioritization for all the markers with P-values ≤0.05 in both data
sets. In this process, we found that in the CMYA5 gene, there were two non-synonymous markers,
rs3828611 and rs10043986, showing nominal significance in both the CATIE and MGS-GAIN
samples. In a combined analysis of both the CATIE and MGS-GAIN samples, rs4704591 was
identified as the most significant marker in the gene. Linkage disequilibrium analyses indicated
that these markers were in low LD (3 828 611–rs10043986, r2 = 0.008; rs10043986–rs4704591, r2
= 0.204). In addition, CMYA5 was reported to be physically interacting with the DTNBP1 gene, a
promising candidate for schizophrenia, suggesting that CMYA5 may be involved in the same
biological pathway and process. On the basis of this information, we performed replication studies
for these three single-nucleotide polymorphisms. The rs3828611 was found to have conflicting
results in our Irish samples and was dropped out without further investigation. The other two
markers were verified in 23 other independent data sets. In a meta-analysis of all 23 replication
samples (family samples, 912 families with 4160 subjects; case–control samples, 11 380 cases and
15 021 controls), we found that both markers are significantly associated with schizophrenia
(rs10043986, odds ratio (OR) = 1.11, 95% confidence interval (CI) = 1.04–1.18, P = 8.2 × 10−4
and rs4704591, OR = 1.07, 95% CI = 1.03–1.11, P = 3.0 × 10−4). The results were also significant
for the 22 Caucasian replication samples (rs10043986, OR = 1.11, 95% CI = 1.03–1.17, P =
0.0026 and rs4704591, OR = 1.07, 95% CI = 1.02–1.11, P = 0.0015). Furthermore, haplotype
conditioned analyses indicated that the association signals observed at these two markers are
independent. On the basis of these results, we concluded that CMYA5 is associated with
schizophrenia and further investigation of the gene is warranted.
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Schizophrenia is a psychiatric disorder with a world-wide prevalence of 1%. It is
characterized by delusions, hallucinations and deficits of cognition and emotion. There is
sufficient data from family and twin studies, suggesting that genetic factors have significant
functions in the etiology of the disease. In recent years, a large number of genetic
association studies have identified many candidate genes for the disease; however, most of
these genes do not have satisfactory replications. Most recently, several genome-wide
associations (GWAs) have been reported.1–6 Of the many potential leads discovered by
these studies, the broad region in chromosome 6p is the most consistent finding.2–4 Another
gene, ZNF804A, has reached global significance when samples from both schizophrenia and
bipolar disorder are combined.6 Other genes, although not reaching genome-wide
significance in initial samples, have consistent replications with many independent
samples.7,8
These recent GWA studies of schizophrenia are not only promising, but also illustrate their
limitations in detecting individual candidate genes with small effects on disease risk.
Alternative approaches are also needed. In this study, we implemented a method that
combines data mining of GWA data sets and bioinformatic prioritization to select promising
candidate genes and follows by verification and meta-analyses of a large number of
independent data sets. Specifically, we conducted GWA analyses of the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) and molecular genetics of
schizophrenia GWA study supported by the genetic association information network (MGS-
GAIN) samples and selected all candidate single-nucleotide polymorphisms (SNPs) with P-
values ≤0.05 in both CATIE and MGS-GAIN data sets. These markers were then analyzed
by comprehensive bioinformatic prioritization procedures. Top candidates emerging from
these analyses were further verified by independent samples. Using this approach, we
analyzed 25 independent samples with a total of over 33 000 individuals and identified two
SNPs, including a non-synonymous SNP, in and around the CMYA5 gene to be
significantly associated with schizophrenia. Here, we report the results from this study.
Materials and methods
Subjects and genotyping
In this study, we used 25 samples with a total of 33 834 subjects, including 912 families
with 4160 subjects, 13 038 cases and 16 636 controls (the overlapping subjects between the
CATIE and MGS-GAIN and MGS non-GAIN were excluded from these numbers). The
CATIE and MGS-GAIN samples were used as our data-mining and hypothesis-generating
samples in the first stage of our two-stage study. The other 23 samples were used as
replication samples. Twenty-four of the 25 samples were of Caucasian ancestry, one sample,
MGS-GAIN-AA, was of African American ancestry. Of these samples, 20 samples were
used in GWA studies by individual groups and the subjects in these samples were typed by
either the Affymetrix or Illumina microarray methods. Five samples, the Irish family
(IFAM), Irish case–control (ICC), Bonn, Pittsburgh and Ashkenazi were typed by the
TaqMan method.9 The quality of genotyping was assessed by individual groups to be
satisfactory. The principle investigators, sample size and genotyping method were listed in
Table 1.
Data mining and bioinformatic prioritization
We used the PLINK program10 to conduct the GWA analyses. The GWA analyses were
conducted with the quality-control filtered markers from the NIMH
(http://nimhgenetics.org/) and GAIN (http://www.ncbi.nlm.nih.gov/sites/entrez?Db = gap)
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repositories for the CATIE and MGS-GAIN samples, respectively. In these analyses, only
Caucasian subjects (CATIE, 492 cases and 523 controls; MGS-GAIN, 1166 cases and 1368
controls including the 236 overlapping controls between the two samples) were used and
markers with a minor allele frequency < 1% or a Hardy–Weinberg equilibrium P-value <
0.0001 were excluded. For the CATIE data set, the seven principle components identified in
the previous study1 were used as covariates and a total of 446 225 markers were analyzed.
For the MGS-GAIN sample, based on previous analyses that there was no significant
stratification found in the sample,2 no covariate was used. The number of markers analyzed
for the MGS GAIN was 727 905. Note that we did not know at the time of GWA analyses
that there were some overlapping subjects between the CATIE and MGS-GAIN samples;
therefore, the two samples used in the data mining and bioinformatic prioritization were not
completely independent. In the subsequent analyses for the common markers between the
two data sets, the 236 overlapping subjects were excluded.
For bioinformatic prioritization, we first selected all markers with P-values ≤0.05 in the two
data sets, and matched them against each other. After the matching, there were 1128 SNPs
with unadjusted P-values ≤0.05 in both the CATIE and GAIN samples. We then conducted
bioinformatic prioritization of these 1128 SNPs based on whether they are located in the
evolutionarily conserved regions, genic regions (exons, introns, untranslated regions, or
within 2 kb of a gene), transcription factor-binding sites, or whether they are located in
known schizophrenia candidate genes (as listed in the sczgene database
http://www.schizophreniaforum.org/res/sczgene/default.asp by June 2008) or whether the
SNPs are non-synonymous. SNPs in each of these categories were assigned an empirical
score: 2 for the non-synonymous and known schizophrenia candidate gene categories, 1 for
the evolutionary conserved region, transcription factor-binding site, untranslated region and
synonymous SNP category and 0.5 for the ‘within 2 kb of a gene’ category. Finally, SNPs
were ranked by the sum of the scores.11
When the CMYA5 gene was identified as the leading candidate, we performed LD structure
analyses of the gene using the HAPLOVIEW program.12 We extracted all markers in the
gene plus 20 kb upstream and downstream sequences for the CATIE and MGS-GAIN
samples, and selected the common markers between the two data sets. Data from the two
data sets were combined. Association analysis for the combined samples was also conducted
using UNPHASED program.13
Replication and meta-analyses of independent samples
On the basis of the prioritization, we initiated genotyping for three SNPs, rs3828611,
rs10043986 and rs4704591, in our IFAM and ICC samples. For rs10043986 and rs4704591,
the results from our Irish samples were consistent with that observed in the CATIE and
MGS-GAIN data sets. The rs3828611 had inconsistent results between our Irish samples;
therefore, was dropped without further investigation. To verify the association observed for
rs10043986 and rs4704591, we requested genotyping of two additional samples (Bonn and
Pittsburgh) and solicited data from GWA studies from 21 independent samples (see Table
1). The MGS-non-GAIN sample also had 208 overlapping control subjects with the CATIE
data set. To maintain the independence among the samples used in the replication study,
these overlapping subjects were removed from the MGS-non-GAIN sample.
Meta-analyses for all samples and replication samples only were conducted. We generated
combined odds ratios (ORs) of the family-based and case– control samples using the
information included in the primary analyses and standard meta-analytic techniques. For the
IFAM sample, we used a PDT-like approach to generate the OR.14 The PDT statistic
compares the number of times a given parental allele (‘risk’ allele) is transmitted versus
non-transmitted and examines allele sharing between affected and unaffected sibling pairs,
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whereas standard case– control approaches examine allele frequencies in cases versus
controls. The parental transmission OR is constructed as (a/c)/(b/d), where a is the
transmissions of the high-risk allele, c is the non-transmissions of the high-risk allele, b is
the transmissions of all other alleles and d is the non-transmissions of all other alleles. In the
sibling pair sample and the population-based samples, which compare case to control allele
frequencies, we construct an OR as (a/c)/(b/d), where a is the number of major alleles
present in cases, c is the number of minor alleles present in cases, b is the number of major
alleles in controls and d is the number of minor alleles present in controls. In each of the EA
case–control samples, we construct an OR as (a/c)/(b/d), where a is the number of major
alleles present in cases, c is the number of minor alleles present in cases, b is the number of
major alleles in controls and d is the number of minor alleles present in controls. In the AA
sample, we fit a logistic regression model including the first principal component of
population stratification as a covariate. The regression coefficient of the effect of the SNP
allowed us to estimate an OR and variance for inclusion in the meta-analysis.
We used formal meta-analytic techniques to combine ORs across study types. We performed
a fixed-effects (Mantel–Haenszel) approach to meta-analysis.15 Before pooling, we
performed Cochran’s (Q) χ2 test of heterogeneity to ensure that each group of studies was
suitable for meta-analysis. Generally, in meta-analysis, when significant heterogeneity is
found, the studies are deemed unsuitable for pooling through a fixed-effects approach. In the
summary meta-analysis of all studies, including the discovery and replication samples, there
was a known overlap in controls between the MGS-GAIN and CATIE samples. We
calculated the asymptotic correlation between the Z-scores of the two studies and performed
a Z-score-based meta-analysis correcting for the correlation because of the shared controls
to ensure appropriate type-I error rate.16
Testing independent effect between rs10043986 and rs4704951
As there were two SNPs showing association in the CMYA5 gene, we evaluated whether the
association signals observed at rs10043986 and rs4704591 were statistically independent.
We took the approach implemented in the PLINK program17 that compares the risk of
haplotypes with identical alleles in the background locus, but different alleles at the locus to
be evaluated. In this case, we inferred all four haplotypes for rs10043986–rs4704591, and
tested the effects of haplotypes with the same allele at rs4704591, but different alleles at
rs10043986. Our aim was to evaluate whether the effect of rs10043986 is independent of
rs4704591. We use the UNPHASED program13 to conduct this analysis as, unlike PLINK, it
is able to combine family data and case–control data for such haplotype-based analyses.
Results
GWA studies data mining and bioinformatic prioritization
From the GWA analyses of the CATIE and MGS-GAIN data sets, there were 24 160 and 68
371 markers with unadjusted P-values ≤0.05, respectively. Although none of the markers in
the CATIE and MGS-GAIN reached genome-wide significance, the number of markers
reaching nominal significance (that is 68 371) was significantly larger than the expected
(that is 37 725) in the MGS-GAIN sample, suggesting that there were markers with true
effects in this pool of nominally significant markers. Of these markers, there were 1228
markers having P≤0.05 in both data sets (Supplementary Table S1). These markers
constituted the pool we used for further bioinformatic prioritization. From these markers, the
informatics procedures revealed several top candidate genes (Table 2). Of these top
candidates, CMYA5 and PTPN21 each had two non-synonymous SNPs. As the two non-
synonymous markers in CMYA5, rs3828611 and rs10043986, had different frequencies, and
were located in two different exons of the gene, we thought they may represent independent
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association signals. In contrast, the two markers in the PTPN21 gene had very similar
frequency. Therefore, we decided to focus on the CMYA5 gene. There were other genes that
had multiple markers with different frequencies (Table 2). These included LRP1B, COLQ,
SERINC1, PTPN21, EML5, NTRK3 and NUTF2. Further analyses of these genes may be
necessary to verify their functions in schizophrenia.
We conducted literature search for the CMYA5 gene and found that it was reported to be
physically interacting with DTNBP1, a leading candidate for schizophrenia that was first
reported in our IFAM sample18 included in this study. We also analyzed single marker
association for the shared SNPs between the CATIE and MGS-GAIN in this interval by
combining CATIE and MGS-GAIN samples together. These analyses identified the most
significant marker, rs4704591, which is located about 9 kb downstream of the gene. Note
that at the time of our GWA analyses, we did not realize that there were overlapping
subjects between the CATIE and MGS-GAIN studies. After removing the overlapping
subjects between the CATIE and MGS-GAIN data sets, an analysis of the combined
samples was performed. The P-values for the three markers were 0.0078 (OR = 1.31, 95%
confidence interval (CI) = 1.07–1.60); 0.0050 (OR; 1.19, 95% CI = 1.06–1.30) and 0.00032
(OR = 1.17, 95% CI = 1.08–1.24) for rs3828611, rs10043986 and rs4704591, respectively
(Figure 1a). The LD analyses of the 27 common markers shared by the CATIE and MGS-
GAIN studies were performed using the HAPLOVIEW program12 for the gene and 20 kb
flanking sequences (Figure 1b). The LD between rs3828611 and rs10043986 was 0.008 (r2),
the LD between rs10043986 and rs4704591 was 0.208 (r2) and the LD between rs3828611
and rs4704591 was 0.016 (r2). As the LDs among these three markers were relatively low, it
was likely that they represented different association signals. There were two other markers
showing similar level of association as rs3828611. The rs6880680 was in high LD with
rs3828611 (r2 = 0.713), its effect may not be independent. The rs6870619 was in low LD
with all other markers in this region. However, as its signal was not as strong as rs4704591
and it did not reach nominal significance in the CATIE sample, it was not pursued.
Verification of CMYA5 association in the Irish samples
On the basis of the data mining and bioinformatic prioritization, we initiated confirmation
study using our IFAM and ICC samples for these three SNPs (rs3828611, rs10043986 and
rs4704591). We used the UNPHASED program,13 which was designed to combine case–
control and family samples and to analyze our combined samples. The results of our Irish
samples support the association of rs10043986 and rs4704951. For rs10043986, both the
case–control and family samples showed the same direction of association for the same
allele as that in the CATIE and MGS-GAIN data sets. However, neither the individual
samples (case–control and family samples) nor the combined samples reached significance.
For rs4704591, the case–control sample had a P-value of 0.2066 and the family sample had
a P-value of 0.0083. The combined case–control and family samples had a P-value of
0.0041. The association of rs3828611 was in the opposite directions between our ICC and
family samples (data not shown). Owing to these conflict results, rs3828611 was dropped
without further investigation.
Meta-analysis of rs10043986 and rs4704591
The results from ICC and family samples were encouraging. For further confirmation, we
solicited data and replication from 23 more independent samples for rs10043986 and
rs4704591. The information of all samples is summarized in Table 1, including the CATIE
and MGS-GAIN used in our data-mining exercise. Overall, we had a total sample size of 33
834 subjects, including 912 families with 4160 subjects, 13 038 cases and 16 636 controls
(the overlapping subjects were excluded from these numbers). Genotyping was conducted
by individual groups using a variety of techniques (see Table 1). To ensure the quality, we
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examined the intensity plots for these two markers. Then, meta-analyses were performed.
For the family samples, the counts for transmitted and untransmitted alleles were used. For
the case–control samples, allele counts for cases and controls were used. In a meta-analysis
of all 23 replication samples (family samples, 912 families with 4160 subjects; case– control
samples, 11 380 cases and 15 021 controls), we found that both markers are significantly
associated with schizophrenia (rs10043986, OR = 1.11, 95% CI = 1.04–1.18, P = 8.2 × 10−4
and rs4704591, OR = 1.07, 95% CI = 1.03–1.11, P = 3.0 × 10−4; Table 3). There was no
significant heterogeneity among the samples (test of heterogeneity: rs10043986, Q = 13.88,
d.f. = 16, P = 0.61; rs4704591, Q = 17.15, d.f. = 19, P = 0.58). The results were also
significant for the 22 Caucasian replication samples (rs10043986, OR = 1.11, 95% CI =
1.03–1.17, P = 0.0026; rs4704591, OR = 1.07, 95% CI = 1.02–1.11, P = 0.0015). The results
for the combined sample including CATIE and MGS GAIN and accounting for the overlap
yields a combined P-value for rs4704591 of 1.11 × 10−5 (Z = 4.39) and for rs10043986 1.47
× 10−5 (Z = 4.33).
rs10043986 and rs4704591 are independently associated with schizophrenia
As we observed that two SNPs in the CMYA5 gene are significantly associated with
schizophrenia, we sought to evaluate whether these two association signals are independent.
In the data-mining data sets, the LD between these two SNPs was relatively low (r2 = 0.208)
and similar results were obtained in our combined European samples (r2 = 0.212), including
the MGS-GAIN and CATIE samples. To test whether the effect of rs10043986 is
independent of that of rs4704591, we inferred the haplotypes from these two markers for the
combined European samples and evaluated whether those haplotypes sharing identical
alleles at rs4704591, but different alleles at rs10043986, have different disease risk. If these
haplotypes have significantly different risks, then the effects of these two markers would be
at least partially independent. Table 4 summarized our results. From the table, it was clear
that haplotypes sharing the same allele background at rs4704591 locus, that is C-C versus T-
C and C-G versus T-G, showed significantly different risks to the disease. In other words,
rs10043986 had an effect independent of that of rs4704591. We also checked the analyses
with the PLINK program using all European case–control samples as PLINK could not
combine family data with case–control data for such analysis. In this analysis, we checked
the independent effect of rs10043986 by comparing the haplotypes sharing the same alleles
at rs4704591 and the result was significant (OR = 1.07, P = 0.0006).
Discussion
In recent years, GWA studies have identified promising candidates in a number of complex
disorders such as type 2 diabetes,19–21 lung cancer,22–24 Parkinson’s disease,25,26
rheumatoid arthritis27 and systemic lupus erythematosus.28 The results for schizophrenia
have generally been less successful. Except the broad region in 6p and the TCF4 and NRGN
regions,4 individual GWA studies have not produced candidates reaching genome-wide
significance yet. Of the many possible factors leading to the outcomes, insufficient power in
these individual studies and the need to correct for a large number of markers tested may be
important factors. However, as aggregated analyses indicated that there may be true findings
among those markers passing nominal significance,3 we believe that this is one of the most
important contributions of GWA studies. Given the fact that there are markers/ genes with
true effects buried in the large number of tested markers, how to identify those markers with
true effects is a practical issue facing the field. In this study, we adapted a two-stage
approach, leading to the identification of two markers in the CMYA5 gene. In the first
hypothesis-generating stage, we conducted GWA analyses for two publicly available data
sets, the CATIE and MGS-GAIN data sets, and selected and ranked markers by statistic and
bioinformatic procedures. These procedures combined statistic and biological evaluations of
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markers with emphasis on the relevance of potential functions in disease. In this study, the
finding of two non-synonymous markers in the CMYA5 gene reaching nominal significance
and the low LD between these markers had an important function in the selection of the
gene for further verification and replication. The reported direct interaction between
CMYA5 and DTNBP1,29 a leading candidate gene for schizophrenia, suggested that these
genes may be involved in a common pathway or biological process. This piece of
information moved the CMYA5 gene to the top of our ranking list. In the second stage, a
total of 23 independent data sets were used to evaluate the significance of these markers by
standard meta-analyses. With these approaches, we were able to find that both markers in
the gene are significantly associated with schizophrenia and there is no heterogeneity across
the samples used in this study, including the MGS-GAIN-AA sample. Furthermore, the
association signals observed in these two markers are independent. As we used a two-stage
design in this study, the results should be evaluated by the number of markers tested in the
second stage despite that we data mined two GWA data sets in our discovery stage. On the
basis of this criterion and considering the large number of independent samples and the
combined sample size, our results are significant. Importantly, one of our markers may have
direct functional consequences as it changes the 4063rd amino acid of the protein from
proline to leucin that would result in a change of residue size and hydrophobicity at the C-
terminus of the protein, a region that was reported to interact with protein kinase regulator
subunit.30 The function of this non-synonymous SNP provides an opportunity to directly test
its effect in the biology of schizophrenia.
Our motivation for this study was to find a way to reduce the penalty imposed by GWAs and
enable us to identify markers with true effects, but not necessarily reaching conventional
levels of genome-wide significance. GWA study is a great tool. Its systematic and
hypothesis-free approach is objective and has great potential. However, in order to
accomplish its aim, sufficient power and/or sample homogeneity are required to compensate
for the steep penalty that has to be paid for testing hundreds of thousands markers. This
creates a situation in which many markers may have true associations, but fail to reach
GWA standards. On the basis of this rationale, we took the approach described in this study,
leading to the identification of the CMYA5 gene as a candidate for schizophrenia.
In retrospect, several aspects of the approach could have been improved. First, we did not
take into account the differences in sample size and power between the MGS-GAIN and
CATIE studies and used the same cutoff (P≤0.05) for both samples. Second, in matching the
markers selected from the two data sets, we did not consider the sign (direction) of the
association. A more objective approach might have been to perform a formal meta-analysis
of the selected markers for the two data sets and take the meta-analysis P-values into
consideration when ranking the markers. Third, in our bioinformatic prioritization, we
focused on single SNP markers. We could have extended these properties to markers in high
LD with these markers, including imputation of untyped markers in the near neighborhood.
Fourth, for a gene or region that had multiple markers associated with the disease, a
haplotype analysis and testing of independent effects could have been conducted to select
the best and independent markers for verification.
Our study provides an example that there are markers with true effects in the GWA studies,
and given sufficiently large sample sizes, these markers can be identified. In this study, the
observed ORs for rs10043986 and rs4704591 were 1.11 and 1.07, respectively, comparable
with that observed in the ZNF804A gene.6 For the CMYA5 gene, there may be other
association signals. The rs3828611 is the other non-synonymous marker selected by our
data-mining procedures that has low LD with both rs10043986 and rs4704591. We did not
pursue it further after the conflicting results from our ICC and family samples. In retrospect,
our termination of rs3828611 may be premature.
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The CMYA5 gene, also known as myospryn, was first identified as a gene associated with
cardiomyopathy.31 The gene is highly expressed in skeletal muscle and heart, and is
modestly expressed in brain (unpublished data). It is reported to be associated with left
ventricular wall thickness in hypertension patients.32 However, the function of the gene
remains unknown. It has been reported to interact with DTNBP1,29,33 the regulator subunit
of protein kinase A30 and desmin34 in muscle cells. The interaction with DTNBP1, another
leading candidate for schizophrenia,35,36 is an interesting lead. DTNBP1 was first reported
to be associated with schizophrenia in our Irish sample.18 Subsequently, many studies,
including several studies that used samples37–41 included in this paper, provided supporting
evidence for the association. This interaction suggests that CMYA5 may also be involved in
the biogenesis of lysosome-related organelles complex 1 (BLOC-1) processes that have been
suggested to be involved in schizophrenia.42–45 The interaction with the regulatory subunit
of protein kinase A suggests that CMYA5 may be involved in the regulation of cAMP signal
pathway, which is also implicated in schizophrenia.46,47 These potential connections
indicate that further studies may test epistatic interaction between these interacting partners,
and examine their functions in the molecular, developmental and pathophysiological
processes in schizophrenia.
In summary, using a two-stage design and with one of the largest sample sizes reported in
recent literature, we report evidence that two SNPs with relatively low LD to each other in
the CMYA5 gene are independently associated with schizophrenia. These results suggest
that there may be many markers in GWA data sets that have true but small effects. To
identify these markers, a large sample size and collaborative work across many groups are
essential.
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(a) Association analysis of the combined samples. The markers selected for replication were
highlighted. (b) LD structure of the 27 markers typed in both CATIE and MGS-GAIN
samples. Pair-wise LD values (r2) were shown. The three markers studied were in low LD,
suggesting that the association signals observed may be different at these markers.
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Table 3
Meta-analyses of rs10043986 and rs4704591 in all replication samples
Sample rs10043986 OR(95% CI)
rs4704591 OR
(95% CI)
MGS non-GAIN 1.16 (0.98–1.38) 0.99 (0.88–1.12)
IFAM 1.34 (0.83–2.17) 1.44 (1.08–1.92)
ICC 1.22 (0.96–1.57) 1.12 (0.94–1.33)
Cardiff — 1.22 (1.06–1.41)
Pittsburgh 1.10 (0.72–1.66) 1.06 (0.80–1.41)
Bonn 1.28 (0.88–1.84) 1.28 (0.99–1.64)
NIMH 1.56 (1.09–2.23) 1.16 (0.91–1.50)
ISC Dublin 1.11 (0.82–1.50) 1.02 (0.84–1.24)
ISC Edinburgh 1.09 (0.76–1.55) 1.04 (0.83–1.30)
ISC Sweden 1 — 1.03 (0.75–1.40)
ISC Sweden 2 1.17 (0.84–1.64) 1.16 (0.91–1.46)
ISC Aberdeen — 1.02 (0.88–1.19)
ISC Portugal — 1.14 (0.89–1.46)
ISC London — 1.12 (0.94–1.35)
ISC Bulgaria 0.97 (0.75–1.26) 1.01 (0.85–1.20)
Copenhagen 0.91 (0.69–1.21) —
Oslo 0.99 (0.72–1.36) 0.96 (0.77–1.19)
Mannheim 0.94 (0.75–1.19) —
Munich 1.12 (0.95–1.33) 1.02 (0.91–1.14)
Dutch 1.03 (0.83–1.28) —
ZHH — 1.08 (0.84–1.38)
Ashkenazi 1.18 (0.92–1.52) 0.93 (0.80–1.09)







Abbreviations: CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; CI, confidence interval; ICC, Irish case–control; IFAM, Irish
family; MAF, minor allele frequency from the MGS-GAIN sample; MGS-GAIN, molecular genetics of schizophrenia genome-wide association
study supported by the genetic association information network; OR, odds ratio.
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